CVS Health (NYSE:CVS) Releases Quarterly Earnings Results, Beats Estimates By $0.30 EPS

CVS Health (NYSE:CVS) posted its quarterly earnings results on Wednesday. The pharmacy operator reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30, Zacks reports. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. CVS Health updated its FY 2025 guidance to 5.750-6.000 EPS.

CVS Health Price Performance

Shares of NYSE CVS opened at $63.23 on Thursday. The firm has a market capitalization of $79.57 billion, a P/E ratio of 16.05, a P/E/G ratio of 0.60 and a beta of 0.61. The firm’s 50-day moving average price is $50.71 and its 200-day moving average price is $55.94. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. CVS Health has a 1-year low of $43.56 and a 1-year high of $80.75.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.21%. CVS Health’s dividend payout ratio is currently 67.51%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CVS. Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $55.00 to $75.00 in a report on Thursday. Mizuho cut their price objective on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. UBS Group lowered their target price on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a report on Tuesday. Evercore ISI lifted their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, January 27th. Finally, Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and an average price target of $69.89.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.